RB1 has been shown to inhibit the E2F1 and E2F2 transcriptional factors [38]; therefore, the allelic deletion of RB1 that was observed in 85% of breast cancer patients in our study is likely to lead to the activation of E2F1 and E2F2. Here, E2F2 is linked to breast carcinoma.